Fan Fei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fan Fei has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Lin Yang
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
4 shared publicationsYi Wang
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, & First Affiliated Hospital, Zhejiang Chinese Medical University, Hangzhou, 310053, China
4 shared publicationsDongxiao Jiang
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
3 shared publicationsMengdi Zhang
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
3 shared publications- Zhong Chen
Key Laboratory of Neuropharmacology and Translational Medicine of Zhejiang Province, School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China
3 shared publications Lilong Yu
Zhejiang Collaborative Innovation Center for the Brain Diseases with Integrative Medicine, Zhejiang Key Laboratory of Neuropsychopharmacology, School of Pharmaceutical Sciences, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Zona incerta somatostatin+ neurons modulate seizure progression through hypothalamic circuits
GABAergic neurons critically regulate epileptic seizures, yet circuit mechanisms mediated by subtype-specific GABAergic neurons in the zona incerta (ZI) remain unclear. Here we reveal the essential role of ZI somatostatin + GABAergic neurons in seizure modulation in the mouse hippocampal kindling model. In vivo Ca 2+ fiber photometry and optogenetics show that ZI GABAergic neurons are gradually activated during seizure progression. Opto-activation inhibits seizure progression, especially the spread of generalized seizures at the later phase, whereas opto-inhibition accelerates it. Although both somatostatin + and parvalbumin + neurons are dynamically recruited during seizure progression, only somatostatin + neurons exert bidirectional seizure modulation. Circuitry mapping and functional modulation demonstrate that ZI somatostatin + neurons projecting to the ventromedial hypothalamus (VMH) glutamatergic neurons suppress the spread of generalized seizures by inhibiting the excitability of VMH-related downstream seizure-spread regions. These findings uncover a cell-type-specific circuit mechanism for seizure regulation by ZI somatostatin + neurons, highlighting these neurons as a potential therapeutic target for epilepsy.
- 29 September 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessZona incerta somatostatin+ neurons modulate seizure progression through hypothalamic circuits
GABAergic neurons critically regulate epileptic seizures, yet circuit mechanisms mediated by subtype-specific GABAergic neurons in the zona incerta (ZI) remain unclear. Here we reveal the essential role of ZI somatostatin + GABAergic neurons in seizure modulation in the mouse hippocampal kindling model. In vivo Ca 2+ fiber photometry and optogenetics show that ZI GABAergic neurons are gradually activated during seizure progression. Opto-activation inhibits seizure progression, especially the spread of generalized seizures at the later phase, whereas opto-inhibition accelerates it. Although both somatostatin + and parvalbumin + neurons are dynamically recruited during seizure progression, only somatostatin + neurons exert bidirectional seizure modulation. Circuitry mapping and functional modulation demonstrate that ZI somatostatin + neurons projecting to the ventromedial hypothalamus (VMH) glutamatergic neurons suppress the spread of generalized seizures by inhibiting the excitability of VMH-related downstream seizure-spread regions. These findings uncover a cell-type-specific circuit mechanism for seizure regulation by ZI somatostatin + neurons, highlighting these neurons as a potential therapeutic target for epilepsy.
- 3 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199, 106213
Glial high-mobility group box 1 translocation promotes post-stroke epileptic seizures
- 3 July 2026
- Published by Elsevier in Neurochemistry International
- Vol. 199, 106213
Glial high-mobility group box 1 translocation promotes post-stroke epileptic seizures
- 25 March 2026
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 42 (6) , 1437-1439
Beyond the Seizure Onset Zone: Fast Ripples as Anchors for Precise Neurostimulation Therapy
- 25 March 2026
- Published by Springer Nature in Neuroscience Bulletin
- Vol. 42 (6) , 1437-1439
Beyond the Seizure Onset Zone: Fast Ripples as Anchors for Precise Neurostimulation Therapy
One‐hertz low‐frequency stimulation of anterior substantia nigra pars reticulata attenuates seizure via biased disinhibitory circuits
Objective: Low‐frequency stimulation (LFS) targeting key seizure nodes holds promising potential for the treatment of epilepsy. The substantia nigra pars reticulata (SNr) plays an important role in seizure control yet has structural heterogeneity. This study aims to explore the therapeutic potential of LFS across different subregions of the SNr. Methods: Different types of seizure models, including kainic acid‐induced hippocampal and neocortical seizure models and a pentetrazol‐induced seizure model, were used to address the therapeutic potential of LFS in different subregions of SNr. Fiber photometry, specific cell ablation, and viral tracing were used to measure the release of different neurotransmitters and heterogeneous circuit organizations of subregions of SNr. Results: We found that 1‐Hz LFS in the anterior SNr (a‐SNr), but not in the posterior SNr (p‐SNr), generally alleviated seizure severity in all three mouse seizure models. Notably, the antiseizure effects were frequency‐dependent, with 100‐Hz high‐frequency stimulation being less effective and 20‐Hz stimulation having hardly any impact. Regarding the mechanism of the discrepancy, fiber photometry showed that 1‐Hz, rather than 20‐ or 100‐Hz, stimulation in the a‐SNr significantly increased γ‐aminobutyric acid release from exogenous inputs compared with stimulation in the p‐SNr, which was further supported by their biased brain‐wide disinhibitory inputs. Significance: These results demonstrate that 1‐Hz LFS in the a‐SNr may be of therapeutic significance in various types of seizures, highlighting the necessity to precisely target the a‐SNr at low frequency for seizure treatment.
One‐hertz low‐frequency stimulation of anterior substantia nigra pars reticulata attenuates seizure via biased disinhibitory circuits
Objective: Low‐frequency stimulation (LFS) targeting key seizure nodes holds promising potential for the treatment of epilepsy. The substantia nigra pars reticulata (SNr) plays an important role in seizure control yet has structural heterogeneity. This study aims to explore the therapeutic potential of LFS across different subregions of the SNr. Methods: Different types of seizure models, including kainic acid‐induced hippocampal and neocortical seizure models and a pentetrazol‐induced seizure model, were used to address the therapeutic potential of LFS in different subregions of SNr. Fiber photometry, specific cell ablation, and viral tracing were used to measure the release of different neurotransmitters and heterogeneous circuit organizations of subregions of SNr. Results: We found that 1‐Hz LFS in the anterior SNr (a‐SNr), but not in the posterior SNr (p‐SNr), generally alleviated seizure severity in all three mouse seizure models. Notably, the antiseizure effects were frequency‐dependent, with 100‐Hz high‐frequency stimulation being less effective and 20‐Hz stimulation having hardly any impact. Regarding the mechanism of the discrepancy, fiber photometry showed that 1‐Hz, rather than 20‐ or 100‐Hz, stimulation in the a‐SNr significantly increased γ‐aminobutyric acid release from exogenous inputs compared with stimulation in the p‐SNr, which was further supported by their biased brain‐wide disinhibitory inputs. Significance: These results demonstrate that 1‐Hz LFS in the a‐SNr may be of therapeutic significance in various types of seizures, highlighting the necessity to precisely target the a‐SNr at low frequency for seizure treatment.
- Open Access
- 3 June 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (4) , 1445-1457
Septal stimulation attenuates hippocampal seizure with subregion specificity
Objective: Deep brain stimulation (DBS) is a promising approach for the treatment of epilepsy. However, the optimal target for DBS and underlying mechanisms are still not clear. Here, we compared the therapeutic effects of DBS on distinct septal subregions, aimed to find the precise targets of septal DBS and related mechanisms for the clinical treatment.Methods: Assisted by behavioral test, electroencephalography (EEG) recording and analyzing, selectively neuronal manipulation and immunohistochemistry, we assessed the effects of DBS on the three septal subregions in kainic acid (KA)‐induced mouse seizure model.Results: DBS in the medial septum (MS) not only delayed generalized seizure (GS) development, but reduced the severity; DBS in the vertical diagonal band of Broca (VDB) only reduced the severity of GS, while DBS in the horizontal diagonal band of Broca (HDB) subregion showed no anti‐seizure effect. Notably, DBS in the MS much more efficiently decreased abnormal activation of hippocampal neurons. EEG spectrum analysis indicated that DBS in the MS and VDB subregions mainly increased the basal hippocampal low‐frequency (delta and theta) rhythm. Furthermore, ablation of cholinergic neurons in the MS and VDB subregions blocked the anti‐seizure and EEG‐modulating effects of septal DBS, suggesting the seizure‐alleviating effect of DBS was dependent on local cholinergic neurons.Significance: DBS in the MS and VDB, rather than HDB, attenuates hippocampal seizure by activation of cholinergic neurons‐augmented hippocampal delta/theta rhythm. This may be of great therapeutic significance for the clinical treatment of epilepsy with septal DBS.Plain Language Summary: The optical target of deep brain stimulation in the septum is still not clear. This study demonstrated that stimulation in the medial septum and vertical diagonal band of Broca subregions, but not the horizontal diagonal band of Broca, could alleviate hippocampal seizure through cholinergic neurons‐augmented hippocampal delta/theta rhythm. This study may shed light on the importance of precise regulation of deep brain stimulation therapy in treating epileptic seizures.
- 3 June 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (4) , 1445-1457
Open AccessSeptal stimulation attenuates hippocampal seizure with subregion specificity
Objective: Deep brain stimulation (DBS) is a promising approach for the treatment of epilepsy. However, the optimal target for DBS and underlying mechanisms are still not clear. Here, we compared the therapeutic effects of DBS on distinct septal subregions, aimed to find the precise targets of septal DBS and related mechanisms for the clinical treatment.Methods: Assisted by behavioral test, electroencephalography (EEG) recording and analyzing, selectively neuronal manipulation and immunohistochemistry, we assessed the effects of DBS on the three septal subregions in kainic acid (KA)‐induced mouse seizure model.Results: DBS in the medial septum (MS) not only delayed generalized seizure (GS) development, but reduced the severity; DBS in the vertical diagonal band of Broca (VDB) only reduced the severity of GS, while DBS in the horizontal diagonal band of Broca (HDB) subregion showed no anti‐seizure effect. Notably, DBS in the MS much more efficiently decreased abnormal activation of hippocampal neurons. EEG spectrum analysis indicated that DBS in the MS and VDB subregions mainly increased the basal hippocampal low‐frequency (delta and theta) rhythm. Furthermore, ablation of cholinergic neurons in the MS and VDB subregions blocked the anti‐seizure and EEG‐modulating effects of septal DBS, suggesting the seizure‐alleviating effect of DBS was dependent on local cholinergic neurons.Significance: DBS in the MS and VDB, rather than HDB, attenuates hippocampal seizure by activation of cholinergic neurons‐augmented hippocampal delta/theta rhythm. This may be of great therapeutic significance for the clinical treatment of epilepsy with septal DBS.Plain Language Summary: The optical target of deep brain stimulation in the septum is still not clear. This study demonstrated that stimulation in the medial septum and vertical diagonal band of Broca subregions, but not the horizontal diagonal band of Broca, could alleviate hippocampal seizure through cholinergic neurons‐augmented hippocampal delta/theta rhythm. This study may shed light on the importance of precise regulation of deep brain stimulation therapy in treating epileptic seizures.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 202-217
Protein Tyrosine Phosphatase SHP2 in Macrophages Acts as an Antiatherosclerotic Regulator in Mice
BACKGROUND: Macrophages have versatile roles in atherosclerosis. SHP2 (Src homology 2 containing protein tyrosine phosphatase 2) has been demonstrated to play a critical role in regulating macrophage activation. However, the mechanism of SHP2 regulation of macrophage function in an atherosclerotic microenvironment remains unknown. METHODS: APOE (apolipoprotein E) or LDLR (low-density lipoprotein receptor) null mice treated with SHP099 were fed a Western diet for 8 weeks, while Shp2 MKO :ApoE −/− or Shp2 MKO :Ldlr −/− mice and exo-AAV8-SHP2 E76K / ApoE −/− mice were fed a Western diet for 12 weeks. In vitro, levels of proinflammatory factors and phagocytic function were then studied in mouse peritoneal macrophages. RNA sequencing was used to identify PPARγ (peroxisome proliferative activated receptor γ) as the key downstream molecule. A PPARγ agonist was used to rescue the phenotypes observed in SHP2-deleted mice. RESULTS: Pharmacological inhibition and selective deletion in macrophages of SHP2 aggravated atherosclerosis in APOE and LDLR null mice with increased plaque macrophages and apoptotic cells. In vitro, SHP2 deficiency in APOE and LDLR null macrophages enhanced proinflammatory polarization and its efferocytosis was dramatically impaired. Conversely, the expression of gain-of-function mutation of SHP2 in mouse macrophages reduced atherosclerosis. The SHP2 agonist lovastatin repressesed macrophage inflammatory activation and enhanced efferocytosis. Mechanistically, RNA sequencing analysis identified PPARγ as a key downstream transcription factor. PPARγ was decreased in macrophages upon SHP2 deletion and inhibition. Importantly, PPARγ agonist decreased atherosclerosis in SHP2 knockout mice, restored efferocytotic defects, and reduced inflammatory activation in SHP2 deleted macrophages. PPARγ was decreased by the ubiquitin-mediated degradation upon SHP2 inhibition or deletion. Finally, we found that SHP2 was downregulated in atherosclerotic vessels. CONCLUSIONS: Overall, SHP2 in macrophages was found to act as an antiatherosclerotic regulator by stabilizing PPARγ in APOE/LDLR null mice.
- 1 January 2024
- Published by Wolters Kluwer Health in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 44 (1) , 202-217
Protein Tyrosine Phosphatase SHP2 in Macrophages Acts as an Antiatherosclerotic Regulator in Mice
BACKGROUND: Macrophages have versatile roles in atherosclerosis. SHP2 (Src homology 2 containing protein tyrosine phosphatase 2) has been demonstrated to play a critical role in regulating macrophage activation. However, the mechanism of SHP2 regulation of macrophage function in an atherosclerotic microenvironment remains unknown. METHODS: APOE (apolipoprotein E) or LDLR (low-density lipoprotein receptor) null mice treated with SHP099 were fed a Western diet for 8 weeks, while Shp2 MKO :ApoE −/− or Shp2 MKO :Ldlr −/− mice and exo-AAV8-SHP2 E76K / ApoE −/− mice were fed a Western diet for 12 weeks. In vitro, levels of proinflammatory factors and phagocytic function were then studied in mouse peritoneal macrophages. RNA sequencing was used to identify PPARγ (peroxisome proliferative activated receptor γ) as the key downstream molecule. A PPARγ agonist was used to rescue the phenotypes observed in SHP2-deleted mice. RESULTS: Pharmacological inhibition and selective deletion in macrophages of SHP2 aggravated atherosclerosis in APOE and LDLR null mice with increased plaque macrophages and apoptotic cells. In vitro, SHP2 deficiency in APOE and LDLR null macrophages enhanced proinflammatory polarization and its efferocytosis was dramatically impaired. Conversely, the expression of gain-of-function mutation of SHP2 in mouse macrophages reduced atherosclerosis. The SHP2 agonist lovastatin repressesed macrophage inflammatory activation and enhanced efferocytosis. Mechanistically, RNA sequencing analysis identified PPARγ as a key downstream transcription factor. PPARγ was decreased in macrophages upon SHP2 deletion and inhibition. Importantly, PPARγ agonist decreased atherosclerosis in SHP2 knockout mice, restored efferocytotic defects, and reduced inflammatory activation in SHP2 deleted macrophages. PPARγ was decreased by the ubiquitin-mediated degradation upon SHP2 inhibition or deletion. Finally, we found that SHP2 was downregulated in atherosclerotic vessels. CONCLUSIONS: Overall, SHP2 in macrophages was found to act as an antiatherosclerotic regulator by stabilizing PPARγ in APOE/LDLR null mice.
- Open Access
- 1 September 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in Chinese Journal of Electrical Engineering
- Vol. 8 (3) , 1-7
Contents
- 1 September 2022
- Published by Institute of Electrical and Electronics Engineers (IEEE) in Chinese Journal of Electrical Engineering
- Vol. 8 (3) , 1-7
Open AccessContents
- Open Access
- 14 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (2) , eabm3381
Nanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy
Electroresponsive and synergistic brain-targeting nanoparticles improve efficacy of pharmacotherapy for epilepsy.
- 14 January 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (2) , eabm3381
Open AccessNanoengineered on-demand drug delivery system improves efficacy of pharmacotherapy for epilepsy
Electroresponsive and synergistic brain-targeting nanoparticles improve efficacy of pharmacotherapy for epilepsy.
- Open Access
- 21 November 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1279
Fry Is Required for Mammary Gland Development During Pregnant Periods and Affects the Morphology and Growth of Breast Cancer Cells
The Fry gene, located on chromosome 13, is an evolutionarily conserved large protein from yeast to human. Our previous study genetically linked the Fry gene with differential susceptibility to mammary carcinogenesis, but whether Fry affects mammary gland development and function, as well as the growth of breast cancer cells, is largely unknown. To define the consequences of Fry loss in the mammary glands, we have generated mice conditionally deficient of the Fry gene in the mammary glands using the Cre-loxP recombination system. We examined multiple phenotypes with male and female homozygous Fry conditional knockout mice (Mfry) and control mice (WT), including body weight, preliminary observations (health and neurological flexes), open field locomotion, sensory abilities, auditory threshold, and glucose metabolism. The loss of Fry in the mammary glands didn't cause a significant difference in these genotypes between Mfry and WT mice. However, our data showed that Fry was required during pregnancy, while it was functionally dispensable in virgin mammary gland development. Loss of Fry led to more lateral buds, and the lobuloalveoli were smaller and showed undistended morphology in mammary glands during late pregnancy. in vitro experiment, ectopic expression of FRY could alter the morphology and significantly suppress the growth and proliferation of the breast cancer cell lines, MDA-MB-231 (ER-/PR-/HER2-, Basal-like) and BT474 (ER+/PR+/HER2+, Luminal B). The following genome-wide transcriptomic analysis of these cells suggested that FRY interacted with protein kinases relevant signaling pathways and induced massive changes in gene expression, including the activation of the Hippo/Yap pathway. Together, our data suggest that the FRY is required for mammary glands developments during pregnant periods, and affects breast cancer cell growth and proliferation.
- 21 November 2019
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 9, 1279
Open AccessFry Is Required for Mammary Gland Development During Pregnant Periods and Affects the Morphology and Growth of Breast Cancer Cells
The Fry gene, located on chromosome 13, is an evolutionarily conserved large protein from yeast to human. Our previous study genetically linked the Fry gene with differential susceptibility to mammary carcinogenesis, but whether Fry affects mammary gland development and function, as well as the growth of breast cancer cells, is largely unknown. To define the consequences of Fry loss in the mammary glands, we have generated mice conditionally deficient of the Fry gene in the mammary glands using the Cre-loxP recombination system. We examined multiple phenotypes with male and female homozygous Fry conditional knockout mice (Mfry) and control mice (WT), including body weight, preliminary observations (health and neurological flexes), open field locomotion, sensory abilities, auditory threshold, and glucose metabolism. The loss of Fry in the mammary glands didn't cause a significant difference in these genotypes between Mfry and WT mice. However, our data showed that Fry was required during pregnancy, while it was functionally dispensable in virgin mammary gland development. Loss of Fry led to more lateral buds, and the lobuloalveoli were smaller and showed undistended morphology in mammary glands during late pregnancy. in vitro experiment, ectopic expression of FRY could alter the morphology and significantly suppress the growth and proliferation of the breast cancer cell lines, MDA-MB-231 (ER-/PR-/HER2-, Basal-like) and BT474 (ER+/PR+/HER2+, Luminal B). The following genome-wide transcriptomic analysis of these cells suggested that FRY interacted with protein kinases relevant signaling pathways and induced massive changes in gene expression, including the activation of the Hippo/Yap pathway. Together, our data suggest that the FRY is required for mammary glands developments during pregnant periods, and affects breast cancer cell growth and proliferation.